ReviewFocus (American Psychiatric Publishing)2023
The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence.
Review in Focus (American Psychiatric Publishing), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Towards a Safe and Effective Lithium Therapeutic Range for Older Adults With Bipolar Disorder: An ISBD Task Force Systematic Review.Bipolar disorders · 2026Pooled it
- Pharmacological maintenance treatment in older age bipolar disorder.Current opinion in psychiatry · 2026Review
- Real-World Assessment of Healthcare Resource Utilization-Defined Manic and Depressive Events Among Patients with Bipolar I Disorder Treated with Cariprazine Versus Aripiprazole.Advances in therapy · 2026Article
- Cariprazine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder: A case report.Biomedical reports · 2026Article
- Lithium in Bipolar Disorder: Renal Mechanisms, Nephrotoxicity Phenotypes, and a Shared-Care Pathway for Clinical Practice.International journal of molecular sciences · 2026Review
- Efficacy and safety of adjunctive transcranial alternating current stimulation in bipolar depression: A randomized controlled trial.Molecular psychiatry · 2026Article
- Evidence-Based Pharmacotherapies for Major Depressive Disorder: A Clinical Update.Psychopharmacology bulletin · 2026Review
- Transcranial Magnetic Stimulation for Bipolar Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials: Stimulation magnétique transcrânienne dans les cas de dépression bipolaire : une revue systématique et une méta-analyse d'essais contrôlés à répartition aléatoire.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2026Review
- From perimenopause to neuroinflammation: Rethinking a case of late-onset mania.PCN reports : psychiatry and clinical neurosciences · 2026Article
- Time to lithium: A case register study of lithium initiation in bipolar disorder.Journal of psychopharmacology (Oxford, England) · 2026Article
- Expert Consensus on the Use of Lurasidone for Bipolar I Depression in Asian Patients.Alpha psychiatry · 2026Article
- Prescribing factors influencing hospital length of stay in patients initiating lithium therapy for acute bipolar or schizoaffective mood episodes.The mental health clinician · 2026Article
- Therapeutic Overlap Between Bipolar Disorder and Migraine: A Systematic Review of Pharmacological Trials.Pharmaceuticals (Basel, Switzerland) · 2026Review
- SSRI versus SNRI initiation and incident bipolar disorder in tertiary psychiatric care: an active-comparator cohort study from the United Arab Emirates.International journal of bipolar disorders · 2026Article
- Does Administration of Low-Dose Aspirin Enhance the Efficacy of Psychotropic Drugs in Patients with Bipolar Disorder, Schizophrenia, and Schizoaffective Disorder?Pharmaceuticals (Basel, Switzerland) · 2026Article
- Views on an antipsychotic regimen administered once every 2 months: a qualitative interview study of people living with bipolar I disorder, caregivers, and prescribers in the USA and Canada.International journal of bipolar disorders · 2026Article
- Article
- Lurasidone-Associated Urinary Retention in a Patient With Bipolar Affective Disorder: A Case Report.Case reports in psychiatry · 2026Article
- Next-Generation Pharmacotherapy for Depressive Disorders: From Novel Compounds to Optimized Use of Available Drugs.Drug design, development and therapy · 2026Review
- Therapeutic apartheid: a cross-sectional assessment of estimated cost, accessibility, affordability, and availability among psychotropic medications across 25 regions.Therapeutic advances in psychopharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bipolar disorder is a complex and heterogeneous psychiatric condition that affects more than 2% of the population. The assessment and treatment of bipolar disorder can be a challenge for clinicians, given its clinical complexity and the rapidly changing treatment landscape with the growing range of treatment options that are becoming available for various phases of the illness. To help clinicians navigate the complexity involved in the assessment and management of bipolar disorder, the guidelines of the 2018 Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) synthesized the evidence on the efficacy, safety, and tolerability of treatments for bipolar disorder and translated it into first-, second-, and third-line treatment recommendations. The main objective of this contribution is to provide clinicians with a summary of the 2018 CANMAT/ISBD guideline recommendations with the addition of any new evidence for the treatment of bipolar disorder across the lifespan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.